Trend Results : Trial Results


Blog Post Results (1-20 of 2838)

FILTER RESULTS

Anti-Pipeline Activist Found Guilty After Being Barred From Mentioning Climate Change

After a short trial lasting just a day and a half, climate activist and retiree Leonard Higgins was found guilty on Wednesday of a serious felony charge for his role in the “valve turner” protest last year that resulted in the brief shutdown of a tar sands pipeline in Montana.

Oral Cannabidiol, PTL101, Meets Goals of Phase 1 Study as Possible Spasticity Treatment

Results of a Phase 1 clinical trial in healthy volunteers show that PTL101, an oral cannabidiol compound, is a safe and effectively delivered potential treatment of spasticity in multiple sclerosis (MS) and for conditions like epilepsy, Harvest One Cannabis announced. Show More Summary

CGM Improves Outcomes for Pregnant Women and Their Babies

This article is reprinted with permission from diaTribe. Find the original article here. By Emma Ryan and Adam Brown New CONCEPTT trial results show improved newborn health and more time-in-range in women with type 1 diabetes using CGM during pregnancy At the recent European Association for the Study of Diabetes (EASD) conference, we saw exciting new results […]

New technique to detect oil in water during LNG processing

Collaborative efforts between the University of Western Australia, Chevron and Woodside have produced promising results using patented technology in a recent field trial.

Stem Cell Therapy Shows Promise for Common Cause of Blindness

Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

PharmaMar presents positive results from a Phase II study of PM1183 in Ewing's sarcoma

In abstract #2768194 entitled "Efficacy and safety of lurbinectedin (PM1183) in Ewing Sarcoma: results from a Phase 2 study" the efficacy and safety results from the Phase II basket trial were presented, in which a group of patientsShow More Summary

CGM Can Help People with Type 2 Diabetes on Injections

This article is reprinted with permission from diaTribe. Find the original article here. By Jeemin Kwon and Adam Brown Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits To date, real-time continuous glucose monitoring (CGM) has been thought of as a technology for people with type 1 diabetes. […]

Do angioplasties and coronary stenting improve symptoms in patients with angina?

Last week, the results of ORBITA were published. This clinical trial tested coronary angioplasty and stenting versus optimal medical management in patients with single-vessel coronary artery disease. It was a resoundingly negative trial, meaning that adding stenting to drug management didn’t result in detectable clinical improvement. Show More Summary

MS: Ozanimod successful in clinical trials

Results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod have now been released.

Philly Gay-Bashing Victims Settle Civil Suit

last weekLGBT / Gay : Joe. My. God.

The Philly Voice reports: The beating of a gay couple three years ago in Center City, which resulted in the high-profile trial of defendant Kathryn Knott, settled a civil suit against their attackers this week. Andrew Haught and Zachary...Show More Summary

NIH study finds donor corneas can be safely preserved for longer period

Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of the cornea. Show More Summary

Ozanimod Successful in Clinical Trials for Multiple Sclerosis

Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod. Ozanimod was invented by scientists at The Scripps Research Institute (TSRI).

High-impact clinical trials yield results that could improve kidney care

New Orleans, LA (November 3, 2017) -- The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2017, October 31-November 5 at the Ernest N. Morial Convention Center in New Orleans, LA.

Results from the ABSORB IV trial reported at TCT 2017

(Cardiovascular Research Foundation) Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

First results from young blood Alzheimer’s trial are criticised

The results from the first trial of young blood as a treatment for Alzheimer’s have been announced, but how the study was done is coming under criticism

Thirty-Day Results of ABSORB IV Demonstrate that Improvements in Bioresorbable Stent Technology and Technique are Still Needed

Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

New Dark Matter Picture Puts the Big Bang on Trial -- "We're Looking At Things All Wrong"

Newest dark matter map hints at where astrophysics must go for breakthroughs. Three astrophysicists discuss how the new results are testing the consensus view of the universe's history and challenging future generations of scientists to solve enduring cosmic mysteries. The...        

Results from the DKCRUSH-V trial reported at TCT 2017 and simultaneously published in JACC

(Cardiovascular Research Foundation) A large-scale randomized trial examining the double kissing (DK) crush two-stent technique compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, found that the DK crush technique was associated with a lower rate of target lesion failure at one year.

Should patients with cardiogenic shock receive culprit lesion only PCI or multivessel PCI?

(Cardiovascular Research Foundation) Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction.

Results from the EXCEL QOL study reported at TCT 2017 and published simultaneously in JACC

(Cardiovascular Research Foundation) New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left main coronary artery disease (LMCAD) receiving percutaneous coronary intervention (PCI) versus coronary...Show More Summary

Copyright © 2015 Regator, LLC